TSEN2

Across TCGA pan-cancer cohorts, TSEN2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TSEN2 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TSEN2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TSEN2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

HNSC, PDAC, and LSCC are the cancer types where TSEN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.701	0.938	<.001	84	view →
PDAC	DFS	Quartile	All	0.281	0.728	.031	11	view →
LSCC	OS	Median	All	0.892	0.725	.012	10	view →
CCRCC	OS	Median	III,IV	0.492	1.000	.019	9	view →
GBM	OS	Tertile	All	0.715	0.383	.001	9	view →
OV	DFS	Tertile	All	1.000	0.691	.044	4	view →
UCEC	OS	Median	All	0.918	0.981	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TSEN2–HNSC (OS)

Open the HNSC breakdown →